Abstract
Inflammatory diseases are a complex group of disorders involving multiple levels of the immune system and as such present a daunting challenge to understand and treat. Contemporary drug development targets individual cytokines, chemokines, and receptors for which we have some knowledge of their function and regulation. One largely unexplored approach is to modify the inflammatory response via targets within the intracellular secretory pathway. This constitutive pathway is responsible for protein processing and trafficking quality control, and is comprised of the endoplasmic reticulum, the Golgi apparatus, and various post-Golgi organelles such as lysosomes, endosomes, secretory granules, and the plasma membrane. Renewed interest in the secretory system has resulted from our expanding appreciation of the role of post-translational processing in protein function, the myriad of inflammatory and other diseases which arise from defects in the secretory system, and the outcome of drug treatments that utilize elements of this pathway to treat human disease. This review will examine the secretory pathway with particular attention to the phenotypes of diseases which result from disruption of its components, as well as the pharmacological agents that utilize the system to modulate aberrant cellular processes.
Keywords: polypeptide chain, glycosphingolipids, trans-Golgi network, Oligosaccharide, Iminosugars, neuraminidase activity, Brefeldin A
Current Topics in Medicinal Chemistry
Title: Targeting the Secretory Pathway for Anti-Inflammatory Drug Development
Volume: 6 Issue: 2
Author(s): Jeffrey W. Ludwig and Mark L. Richards
Affiliation:
Keywords: polypeptide chain, glycosphingolipids, trans-Golgi network, Oligosaccharide, Iminosugars, neuraminidase activity, Brefeldin A
Abstract: Inflammatory diseases are a complex group of disorders involving multiple levels of the immune system and as such present a daunting challenge to understand and treat. Contemporary drug development targets individual cytokines, chemokines, and receptors for which we have some knowledge of their function and regulation. One largely unexplored approach is to modify the inflammatory response via targets within the intracellular secretory pathway. This constitutive pathway is responsible for protein processing and trafficking quality control, and is comprised of the endoplasmic reticulum, the Golgi apparatus, and various post-Golgi organelles such as lysosomes, endosomes, secretory granules, and the plasma membrane. Renewed interest in the secretory system has resulted from our expanding appreciation of the role of post-translational processing in protein function, the myriad of inflammatory and other diseases which arise from defects in the secretory system, and the outcome of drug treatments that utilize elements of this pathway to treat human disease. This review will examine the secretory pathway with particular attention to the phenotypes of diseases which result from disruption of its components, as well as the pharmacological agents that utilize the system to modulate aberrant cellular processes.
Export Options
About this article
Cite this article as:
Ludwig W. Jeffrey and Richards L. Mark, Targeting the Secretory Pathway for Anti-Inflammatory Drug Development, Current Topics in Medicinal Chemistry 2006; 6 (2) . https://dx.doi.org/10.2174/156802606775270314
DOI https://dx.doi.org/10.2174/156802606775270314 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Quantitative Analysis in Cardiovascular Imaging: Current Status
Current Medical Imaging Hypoxia Inducible Factor-1α, Endothelial Progenitor Cells, Monocytes,Cardiovascular Risk, Wound Healing, Cobalt and Hydralazine:A Unifying Hypothesis
Current Drug Targets Dietary Carbohydrates that Modulate the Immune System
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued) Editorial from Guest Editor [Hot topic: Novel Inflammatory Biomarkers in Diseases (Guest Editor: Yu Chen)]
Inflammation & Allergy - Drug Targets (Discontinued) The Involvement of PPARs in the Causes, Consequences and Mechanisms for Correction of Cardiac Lipotoxicity and Oxidative Stress
Current Molecular Pharmacology The Role of Negative Costimulators During Parasitic Infections
Endocrine, Metabolic & Immune Disorders - Drug Targets The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress
Current Cardiology Reviews A Comprehensive Literature Search: Drugs as Possible Triggers of Takotsubo Cardiomyopathy
Current Clinical Pharmacology MCP-1/CCL2 as a Therapeutic Target in Myocardial Infarction and Ischemic Cardiomyopathy
Inflammation & Allergy - Drug Targets (Discontinued) Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design Editorial (Thematic Issue: The Acute Management of Pediatric Heart Failure)
Current Cardiology Reviews Pro- and Anti-Arrhythmic Effects of Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy
Current Cancer Drug Targets The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design Calcium Handling and Arrhythmogenesis
Medicinal Chemistry Indications of Anti-Inflammatory Drugs in Cardiac Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Muscular Dystrophies: Histology, Immunohistochemistry, Molecular Genetics and Management
Current Pharmaceutical Design Alzheimer Disease and Diabetes Mellitus: Do They have Anything in Common?
Current Alzheimer Research Fabry Disease and Cardiovascular Involvement
Current Pharmaceutical Design Old and New Gasotransmitters in the Cardiovascular System: Focus on the Role of Nitric Oxide and Hydrogen Sulfide in Endothelial Cells and Cardiomyocytes
Current Pharmaceutical Biotechnology